OBSTETRIC COAGULOPATHY

SCF ENCYCLOPEDIA ENTRY

OBSTETRIC COAGULOPATHY

SCF-RDOS Registry Code: SCF-RDOS-PPD-HM-006

Disease Type Classification: Hematologic Disorder → Pregnancy-Associated Coagulation Dysfunction → Obstetric Coagulopathy Syndrome

Adaptive Module Activation:

• Universal Core Module
• Hematologic Disease Expansion
• Coagulation System Expansion
• Endothelial Dysfunction Expansion
• Obstetric Emergency Expansion
• Immunothrombotic Expansion
• Multiorgan Perfusion Expansion

⸻

1. SCOPE & POSITIONING

Etiology / Classification

Obstetric Coagulopathy refers to acquired or pregnancy-associated disturbances of coagulation occurring during labor, delivery, or the postpartum period that impair normal hemostasis and increase the risk of severe hemorrhage, thrombosis, multiorgan dysfunction, or maternal death.

Obstetric coagulopathy may arise from:

• Massive postpartum hemorrhage
• Disseminated intravascular coagulation (DIC)
• Placental abruption
• Amniotic fluid embolism
• HELLP syndrome
• Severe preeclampsia
• Acute fatty liver of pregnancy
• Sepsis
• Massive transfusion-related dilutional coagulopathy
• Inherited coagulation disorders unmasked during pregnancy

Within the SCF framework, Obstetric Coagulopathy is classified as:

A maternal hemostatic regulatory collapse syndrome characterized by disruption of coagulation cascade integrity, platelet dysfunction, endothelial instability, consumptive factor depletion, and progressive perfusion failure.

⸻

SCF Classification

SCF Disease Category: Hemostatic Regulatory Failure Syndrome

SCF Functional Class:

Maternal Coagulation-Perfusion Desynchronization Disorder

SCF Fault Tier Classification

⸻

Clinical Significance

Obstetric Coagulopathy is among the most dangerous maternal complications and frequently serves as the final common pathway leading to severe maternal hemorrhage.

Potential complications include:

• Massive postpartum hemorrhage
• Disseminated intravascular coagulation
• Hemorrhagic shock
• Microvascular thrombosis
• Acute kidney injury
• Hepatic injury
• Respiratory failure
• Cerebral ischemia
• Multiorgan dysfunction syndrome
• Maternal mortality

⸻

SCF Domain Alignment

Primary Domains:

• Hematologic
• Coagulation
• Endothelial
• Vascular

Secondary Domains:

• Immune
• Hepatic
• Renal
• Cardiovascular

⸻

2. ETIOPATHOGENIC CORE

Primary Cause

Obstetric Coagulopathy develops when physiologic hemostatic balance becomes overwhelmed by excessive activation, consumption, dilution, inhibition, or dysfunction of coagulation pathways.

Normal pregnancy creates a hypercoagulable state designed to protect against hemorrhage.

When regulatory capacity fails:

• Clotting factors become depleted
• Platelet function becomes impaired
• Endothelial integrity deteriorates
• Hemostasis becomes unstable

Resulting in simultaneous hemorrhagic and thrombotic risk.

⸻

Key Drivers

Driver A — Consumptive Coagulopathy

Massive activation of coagulation causes:

• Fibrin deposition
• Platelet consumption
• Factor depletion

Result:

• Disseminated intravascular coagulation

⸻

Driver B — Massive Hemorrhage

Excessive bleeding causes:

• Coagulation factor loss
• Platelet depletion
• Fibrinogen depletion

Result:

• Progressive hemostatic failure

⸻

Driver C — Endothelial Injury

Common triggers:

• Preeclampsia
• HELLP syndrome
• Sepsis
• Placental pathology

Result:

• Coagulation dysregulation

⸻

Driver D — Dilutional Coagulopathy

Large-volume fluid or blood product administration may cause:

• Clotting factor dilution
• Platelet dilution
• Reduced fibrinogen availability

Result:

• Hemostasis impairment

⸻

Driver E — Immunothrombotic Activation

Inflammatory mediators activate:

• Tissue factor pathways
• Platelet activation
• Complement pathways

Result:

• Hemostatic instability

⸻

3. SCF FAULT ARCHITECTURE

⸻

4. PATHOGENESIS FLOW (SCF LOGIC)

Obstetric Trigger

↓

Endothelial Activation

Coagulation Activation

↓

Excessive Thrombin Generation

↓

Platelet Consumption

↓

Fibrinogen Consumption

↓

Coagulation Factor Depletion

↓

Systemic Coagulopathy

↓

Hemostatic Failure

↓

Hemorrhage

Microvascular Thrombosis

↓

Organ Hypoperfusion

↓

Multiorgan Dysfunction

↓

Maternal Collapse

⸻

5. CLINICAL SPECTRUM

⸻

6. SCF TRINITY FRAMEWORK MAPPING

Trinity Axis I — Structural Integrity

Affected Systems:

• Endothelium
• Platelets
• Fibrin matrix
• Microvasculature

Primary Failure:

• Hemostatic structural collapse

⸻

Trinity Axis II — Energetic Integrity

Affected Systems:

• Cellular oxygen delivery
• Organ perfusion systems
• Mitochondrial energy production

Primary Failure:

• Perfusion-dependent bioenergetic deprivation

⸻

Trinity Axis III — Informational Integrity

Affected Systems:

• Coagulation cascade signaling
• Platelet communication networks
• Endothelial regulatory pathways

Primary Failure:

• Hemostatic signaling desynchronization

⸻

7. COAGULATION DISORDER EXPANSION MODULE

Clinical Subtype Registry

Type A

Consumptive Obstetric Coagulopathy

Characteristics:

• DIC dominant
• Factor depletion

⸻

Type B

Hemorrhage-Induced Coagulopathy

Characteristics:

• Massive blood loss
• Fibrinogen depletion

⸻

Type C

HELLP-Associated Coagulopathy

Characteristics:

• Platelet consumption
• Endothelial injury

⸻

Type D

Sepsis-Associated Coagulopathy

Characteristics:

• Immunothrombotic activation
• Organ dysfunction

⸻

Type E

Dilutional Coagulopathy

Characteristics:

• Massive transfusion
• Factor dilution

⸻

8. MULTI-OMICS PATHOGENESIS MAP

⸻

9. SCF PCR THERAPEUTIC STRATEGY

PREVENTATIVE

Objectives

Prevent progression to severe coagulopathy.

Targets:

• Fibrinogen preservation
• Platelet maintenance
• Endothelial stability
• Early risk recognition

⸻

CURATIVE

Objectives

Restore hemostatic competence.

Targets:

• Factor depletion
• Platelet dysfunction
• Active bleeding
• Coagulation instability

Interventions:

• Hemostatic resuscitation
• Targeted blood product replacement
• Correction of underlying trigger
• Critical care management

⸻

RESTORATIVE

Objectives

Re-establish long-term hemostatic and vascular resilience.

Targets:

• Endothelial recovery
• Coagulation normalization
• Organ reperfusion
• Hematologic restoration

Potential strategies:

• Precision coagulation restoration platforms
• Endothelial regenerative therapeutics
• SCF-derived hemostatic stabilization systems
• Organ recovery optimization programs

⸻

10. CURRENT STANDARD OF CARE

Diagnostic Evaluation

Clinical Assessment

• Active bleeding evaluation
• Hemodynamic monitoring
• Organ dysfunction assessment

⸻

Laboratory Evaluation

Core tests:

• Complete blood count
• Platelet count
• PT/INR
• aPTT
• Fibrinogen
• D-dimer

Advanced tests:

• Thromboelastography (TEG)
• Rotational thromboelastometry (ROTEM)

⸻

Organ Assessment

• Renal function
• Hepatic function
• Lactate monitoring
• Critical care evaluation

⸻

Treatment

Immediate Management

• Correction of underlying cause
• Hemostatic resuscitation
• Blood component replacement

⸻

Targeted Therapy

May include:

• Cryoprecipitate
• Fibrinogen concentrate
• Fresh frozen plasma
• Platelet transfusion
• Packed red blood cells

⸻

Critical Care Support

• Massive transfusion protocols
• Organ support
• Intensive care monitoring

⸻

11. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

SCF Target Cluster A

Precision Hemostasis Platform

Targets:

• Fibrin formation
• Clot stability
• Platelet function

⸻

SCF Target Cluster B

Endothelial Stabilization Platform

Targets:

• Vascular integrity
• Glycocalyx preservation
• Barrier function

⸻

SCF Target Cluster C

Immunothrombotic Regulation Platform

Targets:

• Complement activation
• Cytokine signaling
• Coagulation-inflammation coupling

⸻

SCF Target Cluster D

Perfusion Preservation Platform

Targets:

• Microvascular flow
• Oxygen delivery
• Mitochondrial protection

⸻

12. TRANSLATIONAL BLUEPRINT

Diagnostic Biomarkers

Coagulation

• Fibrinogen
• PT/INR
• aPTT
• D-dimer

Platelet Function

• Platelet count
• Platelet activation markers

Endothelial

• von Willebrand factor
• Soluble thrombomodulin
• Endothelial injury biomarkers

Perfusion

• Lactate
• Base deficit
• Organ injury biomarkers

⸻

Clinical Endpoints

Primary:

• Restoration of effective hemostasis

Secondary:

• Reduction in hemorrhage
• Prevention of thrombosis
• Organ preservation
• Maternal survival

⸻

FDA Translational Pathway

Preclinical

↓

IND

↓

Phase I Safety

↓

Phase II Hemostatic Efficacy

↓

Phase III Maternal Outcomes

↓

NDA/BLA Submission

⸻

13. SCF DBI INTERPRETATION

Decentralized Biological Intelligence Failure

Cellular Layer

Platelets, endothelial cells, and coagulation proteins lose coordinated hemostatic regulation.

⸻

Tissue Layer

Microvascular networks become simultaneously vulnerable to bleeding and thrombosis.

⸻

Organ Layer

Perfusion and oxygen delivery become unstable due to hemostatic collapse.

⸻

System Layer

Coagulation, inflammation, vascular regulation, and organ support systems become profoundly desynchronized.

⸻

Whole-Organism Layer

Maternal survival becomes threatened by failure of the integrated biological systems responsible for maintaining blood integrity and tissue perfusion.

⸻

14. SCF LAYMAN’S SUMMARY

Obstetric Coagulopathy is a serious disorder in which the body’s normal blood-clotting system stops functioning properly during or after childbirth.

According to the SCF model, the condition develops when severe bleeding, inflammation, placental complications, infection, or other obstetric emergencies overwhelm the body’s clotting system. As clotting factors and platelets are consumed or depleted, the body loses the ability to stop bleeding effectively while simultaneously becoming vulnerable to dangerous microscopic blood clots.

Common signs include:

• Excessive bleeding
• Easy bruising
• Oozing from wounds or intravenous sites
• Low blood pressure
• Rapid heart rate
• Organ dysfunction
• Shock in severe cases

Obstetric Coagulopathy is a medical emergency requiring immediate diagnosis and specialized treatment to restore normal clotting and protect maternal life.

⸻

SCF-RDOS INDICATION SUMMARY